Immutep Limited — Form 20-F summary
Period: Fiscal year ended June 30, 2022, with comparisons to fiscal years 2021 and 2020. The request labels the period “2021 Q4,” but this filing is an annual report for FY2022, not a quarterly filing. Financial statements are in Australian dollars (A$) and prepared under IFRS as issued by the IASB and Australian Accounting Standards.
Business context
Immutep is a clinical-stage biotechnology company developing LAG-3-based immunotherapies for cancer and autoimmune disease. Its lead candidate, eftilagimod alpha (efti/IMP321), is being studied in combination therapies; IMP761 is in preclinical development, while IMP701 and IMP731 are licensed to pharmaceutical partners. The company reported 866.2 million ordinary shares outstanding at June 30, 2022 and had no approved products for commercial sale.
Financial and operating metrics
| Metric (A$ unless noted) | FY2022 | FY2021 |
|---|---|---|
| License revenue | 0.17 million | Nil |
| Research material sales | 0.08 million | 0.31 million |
| Grant income | 4.46 million | 3.55 million |
| Total revenue and other income | 6.76 million | 3.97 million |
| Research, development and intellectual-property expenses | 31.34 million | 17.24 million |
| Corporate and administrative expenses | 7.21 million | 6.28 million |
| Net loss | 32.21 million | 29.90 million |
| Net cash used in operating activities | 30.23 million | 17.64 million |
| Cash and cash equivalents at year-end | 80.00 million | 60.59 million |
- Total assets were A$102.17 million and total liabilities A$8.09 million at June 30, 2022; net assets were A$94.08 million.
- Current assets were A$90.81 million versus current liabilities of A$6.41 million. The filing reports no material contingent liabilities or capital-expenditure commitments.
- Debt-related balances included a convertible-note liability with a fair value of A$1.45 million and lease liabilities of A$0.28 million. The remaining note’s disclosed notional amount, including accrued interest, was A$2.08 million and could convert into about 12.2 million ordinary shares. The company also reported A$0.13 million of current warrant liability.
- No conventional profitability margin is meaningful given the absence of product sales and continuing development-stage losses.
- Financing activities provided A$50.33 million, principally from share placements and a share purchase plan. The company issued 118.1 million ordinary shares during FY2022, including shares issued on conversion of notes and exercise of performance rights.
Changes versus the prior year
- Net loss increased by A$2.31 million, while operating cash outflow rose by A$12.59 million. Management attributed the increased spending chiefly to expanded TACTI-002 activity, the start of TACTI-003, and efti/IMP761 manufacturing.
- R&D and intellectual-property expenses rose by A$14.10 million. Corporate and administrative expenses increased A$0.93 million, partly due to the new auditor-attestation requirement under Sarbanes-Oxley Section 404(b).
- Year-end cash increased A$19.40 million, supported by equity financing despite higher operating cash use. Cash runway was estimated by management to extend at least until early 2024, subject to forecast uncertainty.
- Other income included A$4.46 million in R&D grant income and a A$1.23 million foreign-exchange gain. Fair-value movements in warrants produced a A$0.59 million gain in FY2022, compared with an A$8.66 million loss in FY2021; these are not recurring operating revenues.
Outlook, commentary and risks
- Management expects substantial losses and higher R&D expenditure to continue as clinical programs advance. The filing provides no financial earnings or revenue guidance; the early-2024 cash runway estimate is not a guarantee.
- TACTI-002 evaluated efti with pembrolizumab in NSCLC and head-and-neck cancer; recruitment across its cohorts was reported complete in 2021, with interim FY2022 data presented for different cohorts. TACTI-003 is a randomized Phase IIb study in first-line head-and-neck cancer, with pembrolizumab supplied by MSD and trial costs funded by Immutep.
- Management said it was prioritizing first-line NSCLC for later-stage efti development, citing TACTI-002 data and unmet need. FDA Fast Track designation for efti in combination with pembrolizumab in first-line NSCLC was announced after year-end. These are development milestones, not evidence of regulatory approval or commercial success.
- Principal risks include clinical and regulatory failure or delay, patient recruitment, reliance on third-party manufacturers and collaborators, potential need for additional capital and shareholder dilution, foreign-exchange exposure, intellectual-property challenges, competition, and uncertain reimbursement and market acceptance. COVID-19, geopolitical events and macroeconomic conditions could also disrupt trials, supply or financing.
- The independent auditor issued an unqualified opinion on the financial statements and reported effective internal control over financial reporting at June 30, 2022. Grant-income recognition was identified as a critical audit matter because it depends on judgments about qualifying R&D expenditure and government-program rules.
Most important facts for investors to verify
- Confirm current cash, quarterly burn and updated runway against the FY2022 A$80.0 million balance and management’s early-2024 estimate.
- Review subsequent clinical-trial results and regulatory developments, especially the first-line NSCLC program and TACTI-003; distinguish exploratory or interim results from confirmatory evidence.
- Track future R&D and manufacturing costs, grant receipts and financing needs, including the potential dilution from equity issuance and convertible-note conversion.
- Check partner progress and obligations for licensed programs, and verify whether any milestones or royalties have actually been earned or collected.
- Assess the quality and repeatability of grant income, foreign-exchange gains and fair-value movements separately from recurring operating revenue.